Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Xuanzhu Biopharmaceutical Co., Ltd.
軒竹生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2575)

INSIDE INFORMATION
FILING WITH THE CSRC FOR PROPOSED IMPLEMENTATION OF THE H SHARE FULL CIRCULATION BY THE COMPANY

This announcement is made by Xuanzhu Biopharmaceutical Co., Ltd. (the "**Company**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the **"Stock Exchange**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated November 14, 2025 (the "**Announcement**") in relation to the Company's proposed implementation of the H share full circulation. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Board is pleased to announce that on November 17, 2025, the Company has submitted a filing application to the CSRC in relation to the proposed implementation of the H Shares Full Circulation for the conversion of an aggregate of 357,245,794 Unlisted Shares into H Shares on a one-for-one basis. Upon completion of all the filing requirements (including the filing with the CSRC) and obtaining all the relevant approvals (including the approval of the Conversion and Listing by the Stock Exchange) and compliance with all applicable laws, regulations and rules, 357,245,794 Unlisted Shares will be converted into 357,245,794 H Shares, which will be listed and traded on the Stock Exchange.

As at the date of this announcement, the Company has not yet applied to the Stock Exchange for the Conversion and Listing, and the details of the Company's implementation plan in relation to H Share Full Circulation and the Conversion and Listing have not yet been finalized. The Company will make further announcement(s) on the progress of the H Share Full Circulation and the Conversion and Listing in compliance with the Listing Rules as and when appropriate.

The H Share Full Circulation and the Conversion and Listing is subject to other relevant procedures as required by the CSRC, the Stock Exchange and other relevant domestic and overseas regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Xuanzhu Biopharmaceutical Co., Ltd.
Ms. Xu Yanjun
Chairperson of the Board and executive Director

Hong Kong, November 17, 2025

As of the date of this announcement, the Board comprises (i) Ms. Xu Yanjun, Dr. Li Jia Kui and Dr. Shih Cheng-Kon as executive Directors; (ii) Ms. Li Huiying, Mr. Yu Lifeng and Ms. Chen Yanling as non-executive Directors; and (iii) Mr. Liu Shuo, Ms. Wang Yu and Mr. Fan Chi Chiu as independent non-executive Directors.